EntreMed Presents Additional Panzem(R) (2ME2) Preclinical

                   Data at EORTC-NCI-AACR Symposium 
  ROCKVILLE, Md., Sept. 29 /PRNewswire-FirstCall/ -- EntreMed, Inc.
(Nasdaq: ENMD), a clinical-stage pharmaceutical company developing
therapeutics primarily for the treatment of cancer, today announced further
preclinical data on Panzem(R) (2ME2 or 2-methoxyestradiol) demonstrating its
anti-cancer activity and associated plasma drug levels in several animal tumor
models.  These findings, together with previous experiments, indicate that
maintaining increased levels of 2ME2 for longer time periods improves anti-tumor activity.  These data were presented today at the 16th EORTC-NCI-AACR
symposium on "Molecular Targets and Cancer Therapeutics," in Geneva,
(Logo:  http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) 
The new 2ME2 formulation, called Panzem NCD(R), will enter future clinical
trials as an oral suspension given every six hours.  Using a multiple daily
dosing approach, EntreMed is seeking to sustain plasma levels and
concentrations of 2ME2 at higher levels than those reached with the previous
2ME2 capsule formulation.  Further, the new liquid formulation and dosing
schedule of Panzem NCD(R) is intended to maintain plasma levels within the
therapeutic range where anti-cancer activity has been demonstrated in animal
models.  Elan Drug Delivery, Inc. is manufacturing Panzem NCD(R) for EntreMed
using its proprietary NanoCrystal(R) technology. 
Carolyn F. Sidor, M.D., EntreMed Vice President and Chief Medical Officer,
said, "The data presented today have, in part, played an important role in
developing the clinical trial protocol for Panzem NCD(R), our lead drug
candidate.  We look forward to moving this orally-dosed drug candidate into
patient trials in early 2005." 
For detailed information regarding the poster, "Maximizing the anti-tumor
and anti-proliferative effects of 2ME2 by maintaining levels above a threshold
concentration for a defined period of time" by Anthony M. Treston, Glenn
Swartz, Beth Chen, Art Hanson, Wanda Smith, Kirk Volker, Stacy Plum, Carolyn
Sidor, William E. Fogler, and Udo Klein, please refer to
  About Panzem NCD(R) 
Panzem NCD(R), EntreMed's lead clinical candidate, is developed from the
molecule, 2-methoxyestradiol (2ME2). Panzem works through multiple mechanisms
of action (MOA), including inhibiting angiogenesis, disrupting microtubule
formation, down regulating hypoxia inducible factor one-alpha (HIF-1a), and
inducing apoptosis (cell death). The 2ME2 mechanisms that are particularly
relevant to the treatment of cancer involve inhibiting endothelial cell growth
(anti-angiogenic activity) and killing tumor cells directly (pro-apoptotic
activity). As a further result of its multiple MOA, 2ME2 may have potential
therapeutic applications in other non-oncology diseases. 
Although it is a naturally occurring estrogen metabolite, 2ME2 has little
estrogenic activity because it binds poorly to known estrogen receptors. The
activity of 2ME2 has been demonstrated in cell lines that are resistant to
various chemotherapy agents including taxanes (microtubule stabilizing
agents); etoposide, adriamycin and methotrexate (DNA synthesis interfering
agents); and tamoxifen (anti-estrogen agent). 
  About EntreMed 
EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company
developing therapeutic candidates primarily for the treatment of cancer.
Panzem(R) (2-Methoxyestradiol or 2ME2), the Company's lead drug candidate, is
currently in clinical trials for cancer, as well as in preclinical development
for indications outside of oncology. EntreMed's goal is to develop and
commercialize new compounds based on the Company's expertise in angiogenesis,
cell cycle regulation and inflammation -- processes vital to the treatment of
cancer and other diseases. The Company's expertise has also led to the
discovery of new molecules, including analogs of 2ME2, and inhibitors of
fibroblast growth factor-2 (FGF-2), tissue factor pathway (TFP) and proteinase
activated receptor-2 (PAR-2). EntreMed is developing these potential drug
candidates for either in-house advancement or external partnering. 
  Forward Looking Statements 
This release contains, and other statements that EntreMed may make may
contain, forward-looking statements within the meaning of the Private
Securities Litigation Reform Act with respect to the outlook for expectations
for future financial or business performance, strategies, expectations and
goals. Forward-looking statements are typically identified by words or phrases
such as "believe," "feel," "expect," "anticipate," "intend," "outlook,"
"estimate," "target," "assume," "goal," "objective," "plan," "remain," "seek,"
"trend," and variations of such words and similar expressions, or future or
conditional verbs such as "will," "would," "should," "could," "might," "can,"
"may," or similar expressions. Forward-looking statements are subject to
numerous assumptions, risks and uncertainties, which change over time.
Forward-looking statements speak only as of the date they are made, and
EntreMed assumes no duty to update forward-looking statements. Actual results
could differ materially from those currently anticipated due to a number of
factors, including those set forth in EntreMed's Securities and Exchange
Commission filings under "Risk Factors," including risks relating to
EntreMed's need for additional capital and the uncertainty of additional
funding; the early-stage products under development; uncertainties relating to
clinical trials; our success in the further clinical development of Panzem(R);
dependence on third parties; future capital needs; and risks relating to the
commercialization, if any, of the Company's proposed products (such as
marketing, safety, regulatory, patent, product liability, supply, competition
and other risks).

SOURCE  EntreMed, Inc. 

    -0-                             09/29/2004
    /CONTACT:  James Moore, +1-202-258-0776, for EntreMed, Inc./
    /Photo:  Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO
             AP Archive:  http://photoarchive.ap.org
             PRN Photo Desk, 888-776-6555 or 212-782-2840/
    /Web site:  http://www.entremed.com /

CO:  EntreMed, Inc.
ST:  Maryland, Switzerland
-0- Sep/29/2004 14:00 GMT
Press spacebar to pause and continue. Press esc to stop.